Jazz Pharmaceuticals reports 15.2 months median PFS in Phase 2 trial

Jazz Pharmaceuticals (JAZZ) announced long-term data, including the first report of median overall survival from the Phase 2 trial evaluating Ziihera, a dual HER2-targeted bispecific antibody, in combination with chemotherapy for the investigational use in first-line HER2-positive locally advanced nonresectable gastroesophageal adenocarcinoma. The data were featured as a rapid oral presentation at the American Society of Clinical Oncology Annual Meeting, and the results were concurrently published in The Lancet Oncology. Among 41 patients with centrally confirmed HER2-positive tumors, treatment with Ziihera in combination with physician’s choice of chemotherapy resulted in a median progression-free survival of 15.2 months, and a median overall survival of 36.5 months. Median PFS remained stable with the additional four-year follow-up, consistent with previously reported results. Among all 46 patients in the study with HER2-expressing mGEA, median PFS was 12.5 months, and median OS also reached 36.5 months, with the longest observed survival at 57.9 months. Long-term follow-up also demonstrated low discontinuation rates, with no new safety signals observed.